Published in J Thorac Oncol on August 01, 2010
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21
Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol (2011) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs (2013) 0.78
Arterial emboli complicating Cisplatin therapy. Case Rep Oncol Med (2012) 0.75
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs (2015) 0.75
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol (2006) 4.58
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int (2005) 2.29
Predictive adaptive responses to maternal high-fat diet prevent endothelial dysfunction but not hypertension in adult rat offspring. Circulation (2004) 2.28
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol (2007) 2.16
Australopithecus sediba: a new species of Homo-like australopith from South Africa. Science (2010) 1.99
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res (2009) 1.87
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation. J Am Med Inform Assoc (2004) 1.85
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int (2011) 1.76
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 1.75
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study. Radiology (2005) 1.63
Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol (2007) 1.63
Where next for gefitinib in patients with lung cancer? Lancet Oncol (2006) 1.58
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol (2006) 1.58
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet (2002) 1.53
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Mechanism of Mos1 transposition: insights from structural analysis. EMBO J (2006) 1.48
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
Occurrence of UV filters 4-methylbenzylidene camphor and octocrylene in fish from various Swiss rivers with inputs from wastewater treatment plants. Environ Sci Technol (2006) 1.47
Hexabromocyclododecane challenges scientists and regulators. Environ Sci Technol (2005) 1.42
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. Am J Cardiol (2011) 1.38
Australopithecus sediba hand demonstrates mosaic evolution of locomotor and manipulative abilities. Science (2011) 1.37
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
Biomarkers of depression in cancer patients. Cancer (2006) 1.32
A partial pelvis of Australopithecus sediba. Science (2011) 1.31
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol (2011) 1.31
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30
Joint sealants: an overlooked diffuse source of polychlorinated biphenyls in buildings. Environ Sci Technol (2005) 1.30
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.29
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol (2009) 1.26
Targeted transgene expression in neuronal precursors: watching young neurons in the old brain. Eur J Neurosci (2006) 1.26
Three-dimensional fiber architecture of the nonpregnant human uterus determined ex vivo using magnetic resonance diffusion tensor imaging. Anat Rec A Discov Mol Cell Evol Biol (2006) 1.22
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer (2012) 1.22
Endocrine activity and developmental toxicity of cosmetic UV filters--an update. Toxicology (2004) 1.18
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
S-nitrosylation of AtSABP3 antagonizes the expression of plant immunity. J Biol Chem (2008) 1.16
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer (2009) 1.15
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 1.14
A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem (2002) 1.13
Visuomotor priming by pictures of hand postures: perspective matters. Neuropsychologia (2003) 1.12
Anaerobic degradation of decabromodiphenyl ether. Environ Sci Technol (2005) 1.12
Octaheme tetrathionate reductase is a respiratory enzyme with novel heme ligation. Nat Struct Mol Biol (2004) 1.10
Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol (2002) 1.09
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis (2011) 1.08
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics (2009) 1.07
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
Homologues of human macrophage migration inhibitory factor from a parasitic nematode. Gene cloning, protein activity, and crystal structure. J Biol Chem (2002) 1.04
Proteasome: an emerging target for cancer therapy. Anticancer Drugs (2005) 1.04
Expression, purification and preliminary crystallographic studies of a single-point mutant of Mos1 mariner transposase. Acta Crystallogr D Biol Crystallogr (2004) 1.03
Uptake of water via branches helps timberline conifers refill embolized xylem in late winter. Plant Physiol (2014) 1.03
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
Frost drought in conifers at the alpine timberline: xylem dysfunction and adaptations. Ecology (2006) 1.02
A systematic review of computer-assisted diagnosis in diagnostic cancer imaging. Eur J Radiol (2011) 1.02
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol (2005) 1.02
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. Clin Proteomics (2012) 1.01
Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist (2008) 0.99
Making decisions about mammography. BMJ (2005) 0.99
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol (2005) 0.99
Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry. J Proteome Res (2010) 0.99
Structures of immunophilins and their ligand complexes. Curr Top Med Chem (2003) 0.98
Crystal structure of a thermostable lipase from Bacillus stearothermophilus P1. J Mol Biol (2002) 0.98
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res (2010) 0.97
Anaerobic degradation of brominated flame retardants in sewage sludge. Chemosphere (2006) 0.96
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer (2011) 0.96
EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities. Nucleic Acids Res (2010) 0.96
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A (2009) 0.96
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res (2011) 0.96
Blast from the past: melting glaciers as a relevant source for persistent organic pollutants. Environ Sci Technol (2009) 0.94
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med (2014) 0.94
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol (2007) 0.94
Seclusion and restraint in patients with schizophrenia: clinical and biographical correlates. J Nerv Ment Dis (2007) 0.94
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.94
Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health (2013) 0.92
Molecular basis for Jagged-1/Serrate ligand recognition by the Notch receptor. J Biol Chem (2013) 0.92
Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med (2006) 0.92
Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach. Proteomics (2009) 0.92
The upper limb of Australopithecus sediba. Science (2013) 0.92